| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 29 Oct 2026 | 22 Oct 2026 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 inter alia to consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the quarter and half year ended September 30 2026 Please find enclosed outcome of the Board Meeting held on October 29, 2026, inter alia, approving the unaudited financial results for the quarter and half year ended September 30, 2026 as detailed in the enclosed letter. (As per BSE Announcement dated on: 29.10.2026) | ||
| Board Meeting | 21 Sep 2026 | 21 Sep 2026 |
| Outcome of the Board meeting held on Monday, September 21, 2026 | ||
| Board Meeting | 23 Jul 2026 | 16 Jul 2026 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2026. Please find enclosed outcome of the Board Meeting held on July 23, 2026, inter alia, approving the unaudited financial results for the quarter ended June 30, 2026, as detailed in the enclosed letter.. (As per BSE announcement dated on : 23.07.2026) | ||
| Board Meeting | 7 May 2026 | 29 Apr 2026 |
| Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/05/2026 inter alia to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2026 and to recommend the final dividend if any for the financial year 2025-26 Please find enclosed the Outcome of the Board Meeting held on May 07, 2026, inter alia, for the approval of the Financial Results for the quarter and financial year ended March 31, 2026, and other matters as detailed in the enclosed letter. (As per BSE Announcement dated on: 07.05.2026) | ||
| Board Meeting | 28 Jan 2026 | 20 Jan 2026 |
| Quarterly Results Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2025. Outcome of the Board Meeting held on January 28, 2026, for the approval of financial results for the quarter and nine months ended December 31, 2025, and other matter as detailed in the enclosed letter. (As Per BSE Announcement Dated on: 28/01/2026) | ||
Revenue from the operations jumped as much as 19.30% on a y-o-y basis to ₹182 Crore in the December 2025 quarter.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
